Research progress in long-acting human factor Ⅶa
LIANG Ming-zheng
MA Shan-shan
MA Su-yong
Abstract：Human factor Ⅶa (hFⅦa) is the initial enzyme which activates the exogenous coagulation pathway,and has been widely used for therapy of hemorrhage in patients with hemophilia and traumatic hemorrhage in patients without hemophilia,showing satisfactory hemostatic effect.However,it has some problems like other protein drugs,such as short circulating half-life,easiness to be hydrolyzed by enzymes and so on,which limit it's clinical applications greatly.And long-acting protein drugs can prolong residence time in vivo,increase medication compliance of patients,reduce drug-related health care costs,so development of long-acting hFⅦa has become a research hot spot.This article reviews the domestic and foreign research progress in long-acting hFⅦa.
Keywords：human factor Ⅶahalf-lifelong-actingchemical modificationglycosylationfusion protein
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 2943-2946 )